Fenella Kirkham, MD, FRCPCH, is Professor of Paediatric Neurology in the Developmental Neurosciences Unit, UCL Great Ormond Street Institute of Child Health and Clinical and Experimental Sciences, University of Southampton; and a Consultant Paediatric Neurologist, University Hospital Southampton. Her research MD from the University of Cambridge investigated cerebral haemodynamics in children in comas using transcranial Doppler. She focuses on neurocognitive complications of SCD, collaborating with haematologists in England, Europe, the USA, the Middle East, India, and Africa. Her UK, European, Middle Eastern, Indian, Ghanaian, and Tanzanian students and post-docs have successfully defended MSc/Ph.D. theses and published on neuroimaging and cognition. She was a member of the ASH Guidelines and Endpoints working groups. She ran a randomised controlled trial (RCT) of auto-adjusting CPAP with cognitive and MRI endpoints and collaborated with the Kano/Kaduna team in Nigeria on an RCT of low/moderate hydroxurea doses for primary stroke prevention. In 2023, she will commence an RCT of Montelukast in young children (primary endpoint processing speed).
Fenella Kirkham, MD, FRCPCH, is Professor of Paediatric Neurology in the Developmental Neurosciences Unit, UCL Great Ormond Street Institute of Child Health and Clinical and Experimental Sciences, University of Southampton; and a Consultant Paediatric Neurologist, University Hospital Southampton. Her research MD from the University of Cambridge investigated cerebral haemodynamics in children in comas using transcranial Doppler. She focuses on neurocognitive complications of SCD, collaborating with haematologists in England, Europe, the USA, the Middle East, India, and Africa. Her UK, European, Middle Eastern, Indian, Ghanaian, and Tanzanian students and post-docs have successfully defended MSc/Ph.D. theses and published on neuroimaging and cognition. She was a member of the ASH Guidelines and Endpoints working groups. She ran a randomised controlled trial (RCT) of auto-adjusting CPAP with cognitive and MRI endpoints and collaborated with the Kano/Kaduna team in Nigeria on an RCT of low/moderate hydroxurea doses for primary stroke prevention. In 2023, she will commence an RCT of Montelukast in young children (primary endpoint processing speed).